{'fraction_non_alphanumeric': 0.05178571428571429, 'fraction_numerical': 0.033035714285714286, 'mean_word_length': 4.522167487684729, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
102 PROSPECTIVE, RANDOMIZED TRIAL OF METHIOMYL HUMAN GROWTH HORMONE AND/OR OXANDROLONE IN TURNER SYNDROME

To evaluate the efficacy of methionyl human growth hormone (hGH) and oxandrolone (OX), alone and in combination (COMB), in the treatment of Turner syndrome, 71 patients were entered into a randomized, prospective study. After a 6-month observation period, subjects were randomly assigned to either no treatment (CONTROL), OX (0.125 mg/kg/day), hGH (0.125 mg/kg tiw) or COMB. The table shows mean growth rates in cm/yr ± SD (n):All treatment modalities resulted in significant growth acceleration over baseline, and growth velocities were significantly greater than in the control group at both 6 and 12 months (p < 0.0001). COMB was superior to either OX or hGH at both 6 and 12 months (p < 0.05). The mean advance in bone age at 6 months was: CONT 0.2 yrs, OX 0.5 yrs, hGH 0.4 yrs, COMB 0.4 yrs. No significant adverse effects of any treatment modality have been observed to date. These data indicate that hGH, alone or in combination with oxandrolone, promotes short term growth acceleration in Turner syndrome.